These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 23647959)

  • 1. Quantification of hepatitis B surface antigen and E antigen: correlation between Elecsys and architect assays.
    Zhou B; Liu M; Lv G; Zheng H; Wang Y; Sun J; Hou J
    J Viral Hepat; 2013 Jun; 20(6):422-9. PubMed ID: 23647959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantification of hepatitis B e antigen between Elecsys HBeAg and Architect HBeAg assays among patients infected with hepatitis B virus.
    Maylin S; Boyd A; Martinot-Peignoux M; Delaugerre C; Bagnard G; Lapalus M; Zoulim F; Lavocat F; Marcellin P; Simon F; Girard PM; Lacombe K
    J Clin Virol; 2013 Apr; 56(4):306-11. PubMed ID: 23369885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum.
    Wursthorn K; Jaroszewicz J; Zacher BJ; Darnedde M; Raupach R; Mederacke I; Cornberg M; Manns MP; Wedemeyer H
    J Clin Virol; 2011 Apr; 50(4):292-6. PubMed ID: 21273117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantification of hepatitis B surface antigen with the novel DiaSorin LIAISON XL Murex HBsAg Quant: correlation with the ARCHITECT quantitative assays.
    Burdino E; Ruggiero T; Proietti A; Milia MG; Olivero A; Caviglia GP; Marietti M; Rizzetto M; Smedile A; Ghisetti V
    J Clin Virol; 2014 Aug; 60(4):341-6. PubMed ID: 24930708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum hepatitis B surface antigen kinetics in severe reactivation of hepatitis B e antigen negative chronic hepatitis B patients receiving nucleoside/nucleotide analogues.
    Wong GL; Chan HL; Lo AO; Chan HY; Tse CH; Chim AM; Wong VW
    Antivir Ther; 2013; 18(8):979-86. PubMed ID: 23744529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison between Elecsys HBsAg II and architect HBsAg QT assays for quantification of hepatitis B surface antigen among patients coinfected with HIV and hepatitis B virus.
    Maylin S; Boyd A; Delaugerre C; Zoulim F; Lavocat F; Simon F; Girard PM; Lacombe K
    Clin Vaccine Immunol; 2012 Feb; 19(2):242-8. PubMed ID: 22190396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical performance of a new hepatitis B surface antigen quantitative assay with automatic dilution.
    Liu TW; Yeh ML; Huang CF; Lin IL; Huang JF; Dai CY; Chen YL; Chuang WL; Yu ML
    Kaohsiung J Med Sci; 2015 Jan; 31(1):26-33. PubMed ID: 25600917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with serum hepatitis B surface antigen levels and its on-treatment changes in patients under lamivudine therapy.
    Chen J; Wang Z; Zhou B; Wang Y; Hou J
    Antivir Ther; 2012; 17(1):71-9. PubMed ID: 22267471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers.
    Thompson AJ; Nguyen T; Iser D; Ayres A; Jackson K; Littlejohn M; Slavin J; Bowden S; Gane EJ; Abbott W; Lau GK; Lewin SR; Visvanathan K; Desmond PV; Locarnini SA
    Hepatology; 2010 Jun; 51(6):1933-44. PubMed ID: 20512987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the Elecsys HBsAg II Assay and the Architect Assay for Quantification of hepatitis B surface antigen in patients with chronic hepatitis B.
    Karagoz E; Selek MB; Tanoglu A; Hatipoglu M; Ulçay A; Turhan V
    Infez Med; 2016 Dec; 24(4):287-292. PubMed ID: 28011963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D.
    Boglione L; D'Avolio A; Cariti G; Gregori G; Burdino E; Baietto L; Cusato J; Ghisetti V; De Rosa FG; Di Perri G
    Liver Int; 2013 Apr; 33(4):580-5. PubMed ID: 23311449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between Elecsys HBsAg II and Architect assays for quantification of serum hepatitis B surface antigen in Chinese patients with chronic hepatitis B.
    Liu WW; Wang AZ; Xie FY; Hu TT; Zhong Q; Huang S
    Clin Lab; 2015; 61(1-2):141-7. PubMed ID: 25807647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters.
    Tseng TC; Liu CJ; Su TH; Wang CC; Chen CL; Chen PJ; Chen DS; Kao JH
    Gastroenterology; 2011 Aug; 141(2):517-25, 525.e1-2. PubMed ID: 21672542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naïve, e antigen-positive patients.
    Martinot-Peignoux M; Carvalho-Filho R; Lapalus M; Netto-Cardoso AC; Lada O; Batrla R; Krause F; Asselah T; Marcellin P
    J Hepatol; 2013 Jun; 58(6):1089-95. PubMed ID: 23369792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the elecsys HBsAg II assay and the architect assay for quantification of hepatitis B surface antigen in chronic hepatitis B patients.
    Liao CC; Hsu CW; Gu PW; Yeh CT; Lin SM; Chiu CT
    Biomed J; 2015; 38(3):250-6. PubMed ID: 25355387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of response to entecavir therapy in patients with HBeAg-positive chronic hepatitis B based on on-treatment HBsAg, HBeAg and HBV DNA levels.
    Shin JW; Jung SW; Park BR; Kim CJ; Eum JB; Kim BG; Jeong ID; Bang SJ; Lee SH; Kim SR; Park NH
    J Viral Hepat; 2012 Oct; 19(10):724-31. PubMed ID: 22967104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis B.
    Sonneveld MJ; Rijckborst V; Boucher CA; Zwang L; Beersma MF; Hansen BE; Janssen HL
    J Clin Virol; 2011 Jul; 51(3):175-8. PubMed ID: 21592855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A decline in hepatitis B virus surface antigen (hbsag) predicts clearance, but does not correlate with quantitative hbeag or HBV DNA levels.
    Wiegand J; Wedemeyer H; Finger A; Heidrich B; Rosenau J; Michel G; Bock CT; Manns MP; Tillmann HL
    Antivir Ther; 2008; 13(4):547-54. PubMed ID: 18672533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment.
    Fung J; Lai CL; Young J; Wong DK; Yuen J; Seto WK; Yuen MF
    Am J Gastroenterol; 2011 Oct; 106(10):1766-73. PubMed ID: 21826112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B surface antigen quantification as a predictor of seroclearance during treatment in HIV-hepatitis B virus coinfected patients from Sub-Saharan Africa.
    Boyd A; Maylin S; Moh R; Mahjoub N; Gabillard D; Eholié SP; Danel C; Anglaret X; Zoulim F; Girard PM; Delaugerre C; Lacombefor K;
    J Gastroenterol Hepatol; 2016 Mar; 31(3):634-44. PubMed ID: 26313291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.